Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;27S(Suppl):S139-S146.
doi: 10.1016/j.molmet.2019.06.016.

Biomarkers for type 2 diabetes

Markku Laakso  1
Affiliations
Review

Biomarkers for type 2 diabetes

Markku Laakso. Mol Metab. 2019 Sep.

Abstract

Background: The prevalence and incidence of type 2 diabetes (T2D), representing >90% of all cases of diabetes, are increasing rapidly worldwide. Identification of individuals at high risk of developing diabetes is of great importance as early interventions might delay or even prevent full-blown disease. T2D is a complex disease caused by multiple genetic loci in interplay with lifestyle and environmental factors. Recently over 400 distinct association signals were published; these explain 18% of the risk of T2D.

Scope of review: In this review there is a major focus on risk factors and genetic and non-genetic biomarkers for the risk of T2D identified especially in large prospective population-based studies, and studies testing causality of the biomarkers for T2D in Mendelian randomization studies. Another focus is on understanding genome-phenome interplay in the classification of individuals with T2D into subgroups.

Major conclusions: Several recent large population-based studies and their meta-analyses have identified multiple potential genetic and non-genetic biomarkers for the risk of T2D. Combination of genetic variants and physiologically characterized pathways improves the classification of individuals with T2D into subgroups, and is also paving the way to a precision medicine approach, in T2D.

Keywords: Biomarkers; Genomics; Mendelian randomization; Type 2 diabetes.

PubMed Disclaimer

References

    1. Chatterjee S., Khunti K., Davies M.J. Type 2 diabetes. Lancet. 2017;389:2239–2251. - PubMed
    1. Langenberg C., Lotta L.A. Genomic insights into the causes of type 2 diabetes. Lancet. 2018;391:2463–2474. - PubMed
    1. Visscher P.M., Wray N.R., Zhang Q., Sklar P., McCarthy M.I., Brown M.A. 10 years of GWAS discovery: biology, function, and translation. The American Journal of Human Genetics. 2017;101:5–22. - PMC - PubMed
    1. Mahajan A., Taliun D., Thurner M., Robertson N.R., Torres J.M., Rayner N.W. Fine-mapping of an expanded set of type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nature Genetics. 2018;50:1505–1513. - PMC - PubMed
    1. Fuchsberger C., Flannick J., Teslovich T.M., Mahajan A., Agarwala V., Gaulton K.J. Nature. 2016;536:41–47. - PMC - PubMed

Publication types